| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 2876535 | The Annals of Thoracic Surgery | 2011 | 7 Pages |
Abstract
Heart transplantation with plasmapheresis and alemtuzumab in HS LVAD patients, most with a positive crossmatch, does not compromise midterm survival. The expected higher rates of rejection, especially beyond the first postoperative year, demand adjustments in surveillance strategies and immunosuppressive management.
Related Topics
Health Sciences
Medicine and Dentistry
Cardiology and Cardiovascular Medicine
Authors
Scott D. MD, Daniel L. MD, PhD, Giovanni MD, Smita PhD, Alexander MD, N. Alexander MD, Vincent MD,